Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Emmett

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|October 17, 2002
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthmaKetan Sheth, Rohit Borker, Amanda Emmett, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 3, 2005
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesRohit Borker, Amanda Emmett, Priti Jhingran, et al.
Treatments in Respiratory Medicine|June 29, 2004
A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPDJames F Donohue, Christopher Kalberg, Amanda Emmett, et al.
The Journal of Allergy and Clinical Immunology|December 6, 2003
Asthma variability in patients previously treated with beta2-agonists aloneWilliam J Calhoun, Laura B Sutton, Amanda Emmett, et al.
Pulmonary Pharmacology & Therapeutics|June 11, 2008
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibilityEugene R Bleecker, Amanda Emmett, Glenn Crater, et al.
The Open Respiratory Medicine Journal|January 22, 2011
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary diseaseAndras Koser, Jan Westerman, Sanjay Sharma, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 6, 2016
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskHenry Covelli, Bonavuth Pek, Isabelle Schenkenberger, et al.
Respiratory Medicine|July 11, 2008
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsGary T Ferguson, Antonio Anzueto, Richard Fei, et al.
Current Medical Research and Opinion|September 18, 2009
Prevalence of COPD among symptomatic patients in a primary care settingBarbara Yawn, David Mannino, Thomas Littlejohn, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|October 2, 2010
Disease severity and symptoms among patients receiving monotherapy for COPDMark T Dransfield, William Bailey, Glenn Crater, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|October 17, 2002
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthmaKetan Sheth, Rohit Borker, Amanda Emmett, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 3, 2005
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesRohit Borker, Amanda Emmett, Priti Jhingran, et al.
Treatments in Respiratory Medicine|June 29, 2004
A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPDJames F Donohue, Christopher Kalberg, Amanda Emmett, et al.
The Journal of Allergy and Clinical Immunology|December 6, 2003
Asthma variability in patients previously treated with beta2-agonists aloneWilliam J Calhoun, Laura B Sutton, Amanda Emmett, et al.
Pulmonary Pharmacology & Therapeutics|June 11, 2008
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibilityEugene R Bleecker, Amanda Emmett, Glenn Crater, et al.
The Open Respiratory Medicine Journal|January 22, 2011
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary diseaseAndras Koser, Jan Westerman, Sanjay Sharma, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 6, 2016
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskHenry Covelli, Bonavuth Pek, Isabelle Schenkenberger, et al.
Respiratory Medicine|July 11, 2008
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsGary T Ferguson, Antonio Anzueto, Richard Fei, et al.
Current Medical Research and Opinion|September 18, 2009
Prevalence of COPD among symptomatic patients in a primary care settingBarbara Yawn, David Mannino, Thomas Littlejohn, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|October 2, 2010
Disease severity and symptoms among patients receiving monotherapy for COPDMark T Dransfield, William Bailey, Glenn Crater, et al.
Pageof 3